<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-050087</identifier>
<setSpec>0210-5691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">MARS (molecular absorbent recirculatingsystem) as hepatic extracorporeal carein serious acute liver failure of alcoholicetiology</dc:title>
<dc:description xml:lang="en">Acute liver failure with criteria of seriousness and alcoholic etiology is a picture of worldwide distribution, with an elevated mortality, of approximately 50%, that requires admission to the ICU. Acute serious alcoholic hepatitis is defined by a Maddrey score value &gt; 32 and/or spontaneous encephalopathy. Together with the classical treatment with corticosteroids and nutritional supplements, alcoholic abstinence and others such as anti-TNF therapy, we introduce MARS (Molecular Adsorbent recirculating System) as a extracorporeal liver assistance system with detoxification function, that is presented as a support measure that makes it possible to maintain the patient in good conditions until an organ becomes available or until the functional recovery of the native liver. In our case, MARS has shown some spectacular results and above all, results maintained over time, associated to the rest of the therapeutic measures characteristic of this disease</dc:description>
<dc:creator>Séller, G</dc:creator>
<dc:creator>Herrera, M</dc:creator>
<dc:creator>Muñoz, J</dc:creator>
<dc:creator>Mora, J. M</dc:creator>
<dc:creator>Curiel, E</dc:creator>
<dc:creator>Olmedo, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La insuficiencia hepática aguda con criterios de gravedad y etiología enólica es un cuadro de amplia distribución mundial, con una elevada mortalidad, aproximadamente el 50%, y requiere ingreso en la Unidad de Cuidados Intensivos (UCI). La hepatitis alcohólica aguda grave está definida por un valor de Maddrey score &gt; 32 y/o encefalopatía espontánea. Junto al tratamiento clásico con corticoides y suplementos nutricionales, abstinencia alcohólica y otros, como las terapias anti-factor de necrosis tumoral (anti-TNF) introducimos el MARS (molecular adsorbent recirculating system) como sistema de asistencia extracorpórea hepática con función de detoxificación, que se presenta como una medida de soporte que permite mantener al paciente en buenas condiciones hasta la disponibilidad de un órgano o hasta la recuperación funcional del hígado nativo. En nuestro caso, el MARS ha mostrado unos resultados espectaculares y, sobre todo, mantenidos en el tiempo, asociado al resto de las medidas terapéuticas propias a esta patología</dc:description>
<dc:source>Med. intensiva (Madr., Ed. impr.);30(8): 402-406, nov. 2006. tab, graf</dc:source>
<dc:identifier>ibc-050087</dc:identifier>
<dc:title xml:lang="es">MARS (molecular adsorbent recirculating system) como asistencia extracorpórea hepática en el fracaso hepático agudo grave de etiología enólica</dc:title>
<dc:subject>^d8282^s22067</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d29123</dc:subject>
<dc:subject>^d28561</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d38622^s22067</dc:subject>
<dc:subject>^d18001</dc:subject>
<dc:type>article</dc:type>
<dc:date>200611</dc:date>
</metadata>
</record>
</ibecs-document>
